Advantage Alpha Capital Partners LP Cytokinetics Inc Transaction History
Advantage Alpha Capital Partners LP
- $419 Million
- Q3 2024
A detailed history of Advantage Alpha Capital Partners LP transactions in Cytokinetics Inc stock. As of the latest transaction made, Advantage Alpha Capital Partners LP holds 8,292 shares of CYTK stock, worth $402,410. This represents 0.1% of its overall portfolio holdings.
Number of Shares
8,292Holding current value
$402,410% of portfolio
0.1%Shares
1 transactions
Others Institutions Holding CYTK
# of Institutions
409Shares Held
125MCall Options Held
4.6MPut Options Held
2.43M-
Black Rock Inc. New York, NY14.7MShares$712 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$571 Million0.01% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD9.69MShares$470 Million0.31% of portfolio
-
Wellington Management Group LLP Boston, MA7.77MShares$377 Million0.07% of portfolio
-
State Street Corp Boston, MA6.46MShares$313 Million0.01% of portfolio
About CYTOKINETICS INC
- Ticker CYTK
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,144,096
- Market Cap $4.57B
- Description
- Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates i...